Form 4: Guardant Health CTO Reports Routine Stock Transactions

Guardant Health's Chief Technology Officer, Darya Chudova, reported the vesting of restricted stock units and subsequent sale of shares for tax purposes.

Summary

• Darya Chudova, Chief Technology Officer of Guardant Health, Inc. (GH), reported changes in her beneficial ownership of company common stock.
• On September 1, 2025, 316 Restricted Stock Units (RSUs) vested, resulting in the acquisition of 316 shares of common stock at a price of $0.00.
• Concurrently, 161 shares of common stock were disposed of at a price of $67.42 per share, primarily to cover tax withholding obligations related to the RSU vesting.
• Following these transactions, Ms. Chudova directly beneficially owns 81,449 shares of Guardant Health common stock.
• The reported transactions were executed pursuant to a Rule 10b5-1(c) pre-arranged trading plan.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions related to compensation and tax obligations, which are generally neutral events and do not indicate a significant shift in company prospects or insider sentiment.

Positives

• The vesting of Restricted Stock Units (RSUs) represents the fulfillment of a pre-established compensation agreement for the Chief Technology Officer.
• The transactions were conducted under a Rule 10b5-1 plan, indicating they were pre-scheduled and non-discretionary, which is a positive corporate governance practice.

Negatives

• The net effect of the reported transactions is a reduction of 161 shares in the direct beneficial ownership of the Chief Technology Officer.

Future Outlook

The Restricted Stock Unit award granted on November 2, 2021, is scheduled to fully vest on September 1, 2025.

Industry Context

Form 4 filings are routine disclosures for company insiders reporting changes in their stock ownership. These transactions, particularly those related to RSU vesting and tax-related sales, are common across all industries for executive compensation.

Corporate Governance

Stakeholder Impact

• Shareholders: The net disposition of 161 shares by a key executive represents a minor, routine adjustment in insider ownership, unlikely to have a material impact on shareholder value or perception.

Key Dates

Recommendation

This Form 4 filing details routine insider stock transactions, specifically the vesting of Restricted Stock Units and subsequent sales for tax purposes, executed under a Rule 10b5-1 plan. Such transactions are pre-scheduled and non-discretionary, and therefore do not typically reflect a change in the insider's discretionary view of the company's future performance. As such, this filing alone does not provide sufficient new information to warrant a change in an investment recommendation.

Keywords

Guardant Health, GH, Darya Chudova, Chief Technology Officer, CTO, SEC Form 4, Insider Transaction, Stock Vesting, RSU, Rule 10b5-1